About
Product Candidates
- Pipeline
- Tivozanib
- Ficlatuzumab
- AV-203
- AV-380
- AV-353
Publications & Presentations
Media
- Press Releases
- Media Toolkit
Investors
Careers
- Life at AVEO
- Job Openings
Contact

Scarlett Spring

About
Product Candidates
- Pipeline
- Tivozanib
- Ficlatuzumab
- AV-203
- AV-380
- AV-353
Publications & Presentations
Media
- Press Releases
- Media Toolkit
Investors
Careers
- Life at AVEO
- Job Openings
Contact

Still Not Management.php

Click Here To View Our ASCO Poster:

TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal Cell Carcinoma (RCC)

###

© 2020 AVEO Pharmaceuticals, Inc. All rights reserved.

Terms of Use Privacy Policy

About
Product Candidates
- Pipeline
- Tivozanib
- Ficlatuzumab
- AV-203
- AV-380
- AV-353
Publications & Presentations
Media
- Press Releases
- Media Toolkit
Investors
Careers
- Life at AVEO
- Job Openings
Contact